516 related articles for article (PubMed ID: 15545995)
61. Jα33+ MAIT cells play a protective role in TNBS induced intestinal inflammation.
Ruijing X; Mengjun W; Xiaoling Z; Shu P; Mei W; Yingcheng Z; Yuling H; Jinquan T
Hepatogastroenterology; 2012 May; 59(115):762-7. PubMed ID: 22115767
[TBL] [Abstract][Full Text] [Related]
62. Na+/H+ exchanger blockade inhibits enterocyte inflammatory response and protects against colitis.
Németh ZH; Deitch EA; Szabó C; Mabley JG; Pacher P; Fekete Z; Hauser CJ; Haskó G
Am J Physiol Gastrointest Liver Physiol; 2002 Jul; 283(1):G122-32. PubMed ID: 12065299
[TBL] [Abstract][Full Text] [Related]
63. Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: studies in mice with acute trinitrobenzene sulfonic acid colitis.
Reuter KC; Grunwitz CR; Kaminski BM; Steinhilber D; Radeke HH; Stein J
J Pharmacol Exp Ther; 2012 Apr; 341(1):68-80. PubMed ID: 22235147
[TBL] [Abstract][Full Text] [Related]
64. Bidirectional Regulation of Circadian Disturbance and Inflammation in Inflammatory Bowel Disease.
Liu X; Yu R; Zhu L; Hou X; Zou K
Inflamm Bowel Dis; 2017 Oct; 23(10):1741-1751. PubMed ID: 28902123
[TBL] [Abstract][Full Text] [Related]
65. 3,3'-Diindolylmethane decreases VCAM-1 expression and alleviates experimental colitis via a BRCA1-dependent antioxidant pathway.
Huang Z; Zuo L; Zhang Z; Liu J; Chen J; Dong L; Zhang J
Free Radic Biol Med; 2011 Jan; 50(2):228-36. PubMed ID: 21034812
[TBL] [Abstract][Full Text] [Related]
66. CCL2 (pM levels) as a therapeutic agent in Inflammatory Bowel Disease models in mice.
Maharshak N; Hart G; Ron E; Zelman E; Sagiv A; Arber N; Brazowski E; Margalit R; Elinav E; Shachar I
Inflamm Bowel Dis; 2010 Sep; 16(9):1496-504. PubMed ID: 20222120
[TBL] [Abstract][Full Text] [Related]
67. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis.
Panwala CM; Jones JC; Viney JL
J Immunol; 1998 Nov; 161(10):5733-44. PubMed ID: 9820555
[TBL] [Abstract][Full Text] [Related]
68. Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response.
Cenac N; Cellars L; Steinhoff M; Andrade-Gordon P; Hollenberg MD; Wallace JL; Fiorucci S; Vergnolle N
Inflamm Bowel Dis; 2005 Sep; 11(9):792-8. PubMed ID: 16116312
[TBL] [Abstract][Full Text] [Related]
69. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.
Laverny G; Penna G; Vetrano S; Correale C; Nebuloni M; Danese S; Adorini L
Immunol Lett; 2010 Jun; 131(1):49-58. PubMed ID: 20350569
[TBL] [Abstract][Full Text] [Related]
70. [Changes in tight junction protein expression and permeability of colon mucosa in rats with dextran sulfate sodium-induced inflammatory bowel disease].
Rao YX; Chen J; Chen LL; Gu WZ; Shu XL
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):976-81. PubMed ID: 23234790
[TBL] [Abstract][Full Text] [Related]
71. Recombinant human MFG-E8 ameliorates colon damage in DSS- and TNBS-induced colitis in mice.
Zhang Y; Brenner M; Yang WL; Wang P
Lab Invest; 2015 May; 95(5):480-90. PubMed ID: 25751740
[TBL] [Abstract][Full Text] [Related]
72. Proteinase-activated receptor-4 evoked colorectal analgesia in mice: an endogenously activated feed-back loop in visceral inflammatory pain.
Annaházi A; Dabek M; Gecse K; Salvador-Cartier C; Polizzi A; Rosztóczy A; Róka R; Theodorou V; Wittmann T; Bueno L; Eutamene H
Neurogastroenterol Motil; 2012 Jan; 24(1):76-85, e13. PubMed ID: 22044612
[TBL] [Abstract][Full Text] [Related]
73. Colonic expression of the peptide transporter PEPT1 is downregulated during intestinal inflammation and is not required for NOD2-dependent immune activation.
Wuensch T; Ullrich S; Schulz S; Chamaillard M; Schaltenberg N; Rath E; Goebel U; Sartor RB; Prager M; Büning C; Bugert P; Witt H; Haller D; Daniel H
Inflamm Bowel Dis; 2014 Apr; 20(4):671-84. PubMed ID: 24583477
[TBL] [Abstract][Full Text] [Related]
74. Erythropoietin reduces the development of experimental inflammatory bowel disease.
Cuzzocrea S; Mazzon E; Di Paola R; Patel NS; Genovese T; Muià C; De Sarro A; Thiemermann C
J Pharmacol Exp Ther; 2004 Dec; 311(3):1272-80. PubMed ID: 15302898
[TBL] [Abstract][Full Text] [Related]
75. Experimental models of inflammatory bowel disease.
Stadnicki A; Colman RW
Arch Immunol Ther Exp (Warsz); 2003; 51(3):149-55. PubMed ID: 12894869
[TBL] [Abstract][Full Text] [Related]
76. Astragaloside IV ameliorates 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis implicating regulation of energy metabolism.
Jiang XG; Sun K; Liu YY; Yan L; Wang MX; Fan JY; Mu HN; Li C; Chen YY; Wang CS; Han JY
Sci Rep; 2017 Feb; 7():41832. PubMed ID: 28150820
[TBL] [Abstract][Full Text] [Related]
77. Methods of inducing inflammatory bowel disease in mice.
Maxwell JR; Brown WA; Smith CL; Byrne FR; Viney JL
Curr Protoc Pharmacol; 2009 Dec; Chapter 5():Unit5.58. PubMed ID: 22294404
[TBL] [Abstract][Full Text] [Related]
78. Oral administration of docosahexaenoic acid attenuates colitis induced by dextran sulfate sodium in mice.
Cho JY; Chi SG; Chun HS
Mol Nutr Food Res; 2011 Feb; 55(2):239-46. PubMed ID: 20824662
[TBL] [Abstract][Full Text] [Related]
79. Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
González-García A; Sánchez-Ruiz J; Flores JM; Carrera AC
Gastroenterology; 2010 Apr; 138(4):1374-83. PubMed ID: 20004201
[TBL] [Abstract][Full Text] [Related]
80. Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis.
Shen C; Bullens D; Kasran A; Maerten P; Boon L; Aerts JM; Van Assche G; Geboes K; Rutgeerts P; Ceuppens JL
Int Immunopharmacol; 2004 Jul; 4(7):939-51. PubMed ID: 15182733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
